(Q28286055)

1

0 references

Jeannette Texier-Maugein

2

0 references

Marie-Claude Saux

4

0 references

Emmanuel Boselli

Carbapenems: past, present, and future

5

0 references

language of work or name

English

0 references

publication date

February 2013

0 references

published in

Journal of Chemotherapy

0 references

volume

25

0 references

issue

1

0 references

page(s)

1-17

0 references

cites work

1 reference

https://api.crossref.org/works/10.1179/1973947812Y.0000000032

Clinical review: balancing the therapeutic, safety, and economic issues underlying effective antipseudomonal carbapenem use

20 April 2017

1 reference

https://api.crossref.org/works/10.1179/1973947812Y.0000000032

Carbapenemases: the versatile beta-lactamases

20 April 2017

1 reference

https://api.crossref.org/works/10.1179/1973947812Y.0000000032

Results of a clinical trial of clinafloxacin versus imipenem/cilastatin for intraabdominal infections

20 April 2017

1 reference

https://api.crossref.org/works/10.1179/1973947812Y.0000000032

Overview of seizure-inducing potential of doripenem

20 April 2017

1 reference

https://api.crossref.org/works/10.1179/1973947812Y.0000000032

Carbapenems: a potent class of antibiotics

20 April 2017

1 reference

https://api.crossref.org/works/10.1179%2F1973947812Y.0000000032

New developments in carbapenems

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F1973947812Y.0000000032

Doripenem: position in clinical practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F1973947812Y.0000000032

21 January 2018

Parenteral carbapenems

1 reference

https://api.crossref.org/works/10.1179%2F1973947812Y.0000000032

Affinity of doripenem and comparators to penicillin-binding proteins in Escherichia coli and Pseudomonas aeruginosa

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F1973947812Y.0000000032

In vitro activity of doripenem against Acinetobacter baumannii clinical isolates

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F1973947812Y.0000000032

Characteristics of doripenem: a new broad-spectrum antibiotic

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F1973947812Y.0000000032

Relevance of resistance levels to carbapenems and integron-borne blaIMP-1, blaIMP-7, blaIMP-10 and blaVIM-2 in clinical isolates of Pseudomonas aeruginosa

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F1973947812Y.0000000032

Multiplex real-time PCR assay for detection and classification of Klebsiella pneumoniae carbapenemase gene (bla KPC) variants

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F1973947812Y.0000000032

Structural basis for the extended substrate spectrum of CMY-10, a plasmid-encoded class C beta-lactamase

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F1973947812Y.0000000032

Rapid evolution and spread of carbapenemases among Enterobacteriaceae in Europe

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F1973947812Y.0000000032

Meropenem activity against European isolates: report on the MYSTIC (Meropenem Yearly Susceptibility Test Information Collection) 2006 results

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F1973947812Y.0000000032

In vitro killing of parenteral beta-lactams against standard and high inocula of extended-spectrum beta-lactamase and non-ESBL producing Klebsiella pneumoniae

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F1973947812Y.0000000032

Comparative antianaerobic activities of doripenem determined by MIC and time-kill analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F1973947812Y.0000000032

Doripenem (S-4661), a novel carbapenem: comparative activity against contemporary pathogens including bactericidal action and preliminary in vitro methods evaluations

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F1973947812Y.0000000032

Antimicrobial-induced release of endotoxin from Pseudomonas aeruginosa: comparison of in vitro and animal models

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F1973947812Y.0000000032

Bactericidal activities of meropenem and ertapenem against extended-spectrum-beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in a neutropenic mouse thigh model

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F1973947812Y.0000000032

Comparative pharmacokinetics of the carbapenems: clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F1973947812Y.0000000032

Doripenem: a review of its use in the treatment of bacterial infections.

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F1973947812Y.0000000032

Pharmacokinetics of ertapenem in healthy young volunteers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F1973947812Y.0000000032

Carbapenems in the USA: focus on doripenem

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F1973947812Y.0000000032

Multiple-dose pharmacokinetics of imipenem-cilastatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F1973947812Y.0000000032

Ertapenem in critically ill patients with early-onset ventilator-associated pneumonia: pharmacokinetics with special consideration of free-drug concentration.

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F1973947812Y.0000000032

Comparative disposition of [14C]ertapenem, a novel carbapenem antibiotic, in rat, monkey and man.

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F1973947812Y.0000000032

Disposition, metabolism, and excretion of [14C]doripenem after a single 500-milligram intravenous infusion in healthy men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F1973947812Y.0000000032

Comparative review of the carbapenems

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F1973947812Y.0000000032

An overview of the pharmacology of imipenem/cilastatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F1973947812Y.0000000032

Pharmacokinetics of meropenem in patients with renal failure and patients receiving renal replacement therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F1973947812Y.0000000032

Pneumonia: the impact of risk factors on the outcome of treatment with meropenem and ceftazidime.

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F1973947812Y.0000000032

Carbapenems in the treatment of severe community-acquired pneumonia in hospitalized elderly patients: a comparative study against standard therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F1973947812Y.0000000032

A study evaluating the efficacy, safety, and tolerability of ertapenem versus ceftriaxone for the treatment of community-acquired pneumonia in adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F1973947812Y.0000000032

A prospective, randomized, double-blind multicenter comparison of parenteral ertapenem and ceftriaxone for the treatment of hospitalized adults with community-acquired pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F1973947812Y.0000000032

Treatment of severe pneumonia in hospitalized patients: results of a multicenter, randomized, double-blind trial comparing intravenous ciprofloxacin with imipenem-cilastatin. The Severe Pneumonia Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F1973947812Y.0000000032

Treatment of severe nosocomial pneumonia: a prospective randomised comparison of intravenous ciprofloxacin with imipenem/cilastatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F1973947812Y.0000000032

Levofloxacin compared with imipenem/cilastatin followed by ciprofloxacin in adult patients with nosocomial pneumonia: A multicenter, prospective, randomized, open-label study

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F1973947812Y.0000000032

Cefepime versus imipenem-cilastatin for treatment of nosocomial pneumonia in intensive care unit patients: a multicenter, evaluator-blind, prospective, randomized study

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F1973947812Y.0000000032

Comparison of piperacillin/tazobactam and imipenem/cilastatin, both in combination with tobramycin, administered every 6 h for treatment of nosocomial pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F1973947812Y.0000000032

Combined imipenem/cilastatin and tobramycin therapy of multiresistant Pseudomonas aeruginosa in cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F1973947812Y.0000000032

Clinical evaluation of meropenem versus ceftazidime for the treatment of Pseudomonas spp. infections in cystic fibrosis patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F1973947812Y.0000000032

The efficacy and safety of meropenem and tobramycin vs ceftazidime and tobramycin in the treatment of acute pulmonary exacerbations in patients with cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F1973947812Y.0000000032

Meta-analysis of the clinical outcome of carbapenem monotherapy in the adjunctive treatment of intra-abdominal infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F1973947812Y.0000000032

Meropenem versus imipenem/cilastatin in the treatment of intra-abdominal infections.

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F1973947812Y.0000000032

Meropenem versus imipenem/cilastatin in intra-abdominal infections requiring surgery. Meropenem Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F1973947812Y.0000000032

Meropenem (1.5 g/day) is as effective as imipenem/cilastatin (2 g/day) for the treatment of moderately severe intra-abdominal infections.

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F1973947812Y.0000000032

Antibiotic monotherapy with meropenem in the surgical management of intra-abdominal infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F1973947812Y.0000000032

Meropenem monotherapy versus cefotaxime plus metronidazole combination treatment for serious intra-abdominal infections.

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F1973947812Y.0000000032

Meta-analysis: ertapenem for complicated intra-abdominal infections.

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F1973947812Y.0000000032

Efficacy and tolerability of IV doripenem versus meropenem in adults with complicated intra-abdominal infection: a phase III, prospective, multicenter, randomized, double-blind, noninferiority study

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F1973947812Y.0000000032

Newer carbapenems for urinary tract infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F1973947812Y.0000000032

Piperacillin 2 g/tazobactam 0.5 g is as effective as imipenem 0.5 g/cilastatin 0.5 g for the treatment of acute uncomplicated pyelonephritis and complicated urinary tract infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F1973947812Y.0000000032

A Multicenter Comparative Study of Meropenem and Imipenem/Cilastatin in the Treatment of Complicated Urinary Tract Infections in Hospitalized Patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F1973947812Y.0000000032

A prospective, multicenter, randomized, double-blind study comparing ertapenem and ceftriaxone followed by appropriate oral therapy for complicated urinary tract infections in adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F1973947812Y.0000000032

Ertapenem versus ceftriaxone followed by appropriate oral therapy for treatment of complicated urinary tract infections in adults: results of a prospective, randomized, double-blind multicenter study

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F1973947812Y.0000000032

Intravenous doripenem at 500 milligrams versus levofloxacin at 250 milligrams, with an option to switch to oral therapy, for treatment of complicated lower urinary tract infection and pyelonephritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F1973947812Y.0000000032

Empirical antibiotic monotherapy for febrile neutropenia: systematic review and meta-analysis of randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F1973947812Y.0000000032

Ertapenem once daily versus piperacillin-tazobactam 4 times per day for treatment of complicated skin and skin-structure infections in adults: results of a prospective, randomized, double-blind multicenter study

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F1973947812Y.0000000032

Meropenem versus imipenem-cilastatin for the treatment of hospitalized patients with complicated skin and skin structure infections: results of a multicenter, randomized, double-blind comparative study

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F1973947812Y.0000000032

Ertapenem versus piperacillin/tazobactam for diabetic foot infections (SIDESTEP): prospective, randomised, controlled, double-blinded, multicentre trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F1973947812Y.0000000032

Pharmacokinetic issues for antibiotics in the critically ill patient

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F1973947812Y.0000000032

Pharmacokinetic evaluation of meropenem and imipenem in critically ill patients with sepsis

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F1973947812Y.0000000032

Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F1973947812Y.0000000032

Is continuous infusion of beta-lactam antibiotics worthwhile?--efficacy and pharmacokinetic considerations

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F1973947812Y.0000000032

Optimal meropenem concentrations to treat multidrug-resistant Pseudomonas aeruginosa septic shock

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F1973947812Y.0000000032

Meropenem by continuous versus intermittent infusion in ventilator-associated pneumonia due to gram-negative bacilli

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F1973947812Y.0000000032

Pharmacokinetic-pharmacodynamic-model-guided doripenem dosing in critically ill patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F1973947812Y.0000000032

Molecular mechanisms disrupting porin expression in ertapenem-resistant Klebsiella and Enterobacter spp. clinical isolates from the UK.

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F1973947812Y.0000000032

Effects of clinical breakpoint changes in CLSI guidelines 2010/2011 and EUCAST guidelines 2011 on antibiotic susceptibility test reporting of Gram-negative bacilli.

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F1973947812Y.0000000032

Continuous infusion of beta-lactams.

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F1973947812Y.0000000032

Relationship of minimal inhibitory concentration and bactericidal activity to efficacy of antibiotics for treatment of ventilator-associated pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F1973947812Y.0000000032

Absence of convulsive liability of doripenem, a new carbapenem antibiotic, in comparison with beta-lactam antibiotics

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F1973947812Y.0000000032

Doripenem monohydrate, a broad-spectrum carbapenem antibiotic

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F1973947812Y.0000000032

In vitro activities of ertapenem (MK-0826) against recent clinical bacteria collected in Europe and Australia

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F1973947812Y.0000000032

Antimicrobial activity of doripenem (S-4661): a global surveillance report (2003).

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F1973947812Y.0000000032

In vitro antimicrobial activity of doripenem, a new carbapenem

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F1973947812Y.0000000032

Comparative in-vitro activities of ertapenem against aerobic bacterial pathogens isolated from patients with complicated intra-abdominal infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F1973947812Y.0000000032

Antimicrobial resistance rates and clonality results from the Meropenem Yearly Susceptibility Test Information Collection (MYSTIC) programme: report of year five (2003).

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F1973947812Y.0000000032

Activity of a novel carbapenem, doripenem, against anaerobic pathogens

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F1973947812Y.0000000032

In vitro activities of doripenem, a new broad-spectrum carbapenem, against recently collected clinical anaerobic isolates, with emphasis on the Bacteroides fragilis group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F1973947812Y.0000000032

Comparative activities of doripenem versus isolates, mutants, and transconjugants of Enterobacteriaceae and Acinetobacter spp. with characterized beta-lactamases

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F1973947812Y.0000000032

The utility of diffusion chambers as models for the description of drug disposition.

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F1973947812Y.0000000032

Meropenem pharmacokinetics and penetration into an inflammatory exudate

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F1973947812Y.0000000032

Intrapulmonary pharmacokinetics and pharmacodynamics of meropenem

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F1973947812Y.0000000032

Tissue penetration of Meropenem in patients undergoing gynecologic surgery

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F1973947812Y.0000000032

The pharmacokinetics and pharmacodynamics of meropenem in the cerebrospinal fluid of neurosurgical patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F1973947812Y.0000000032

Tissue penetration by ertapenem, a parenteral carbapenem administered once daily, in suction-induced skin blister fluid in healthy young volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F1973947812Y.0000000032

Ertapenem peritoneal fluid concentrations in adult surgical patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F1973947812Y.0000000032

Intraabdominal tissue concentration of ertapenem

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F1973947812Y.0000000032

Penetration of ertapenem into different pulmonary compartments of patients undergoing lung surgery

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F1973947812Y.0000000032

Diffusion of ertapenem into bone and synovial tissues.

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F1973947812Y.0000000032

Peritoneal penetration of doripenem after intravenous administration in abdominal-surgery patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F1973947812Y.0000000032

Penetration of doripenem into prostatic tissue following intravenous administration in prostatectomy patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F1973947812Y.0000000032

Pharmacokinetics and pharmacodynamics of imipenem during continuous renal replacement therapy in critically ill patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F1973947812Y.0000000032

Meropenem and continuous renal replacement

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F1973947812Y.0000000032

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F1973947812Y.0000000032

Doripenem pharmacokinetics in critically ill patients receiving continuous hemodiafiltration (CHDF).

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F1973947812Y.0000000032

Efficacy and safety of ertapenem versus piperacillin-tazobactam for the treatment of intra-abdominal infections requiring surgical intervention.

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F1973947812Y.0000000032

Randomized, multicenter, double-blind study of efficacy, safety, and tolerability of intravenous ertapenem versus piperacillin/tazobactam in treatment of complicated intra-abdominal infections in hospitalized adults.

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F1973947812Y.0000000032

Ertapenem monotherapy versus combination therapy with ceftriaxone plus metronidazole for treatment of complicated intra-abdominal infections in adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F1973947812Y.0000000032

Ertapenem versus ceftriaxone and metronidazole as treatment for complicated intra-abdominal infections.

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F1973947812Y.0000000032